Clinical Trial

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

Name: Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects — clinical trial record (NCT07486895)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.

Trial Details

NCT Number	NCT07486895
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	Healthy Adult Participants
Enrollment	44 participants
Start Date	2023-03-08
Primary Completion	2023-05-18 (estimated)
Study Completion	2023-05-18 (estimated)
Updated on ClinicalTrials.gov	2026-03-23